Provided by Tiger Trade Technology Pte. Ltd.

Amgen

421.51
-2.1300-0.50%
Post-market: 423.151.64+0.39%19:57 EDT
Volume:3.13M
Turnover:1.32B
Market Cap:226.97B
PE:26.18
High:426.59
Open:424.01
Low:420.63
Close:423.64
52wk High:447.03
52wk Low:283.00
Shares:538.48M
Float Shares:536.99M
Volume Ratio:1.10
T/O Rate:0.58%
Dividend:9.80
Dividend Rate:2.32%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:19.42
PE(LYR):29.62

Loading ...

Amgen Inc. Stock Advances 4.3%, Outperforms Peers

Dow Jones
·
Sep 23

Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales

Reuters
·
Sep 23

Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading

MT Newswires Live
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

TIPRANKS
·
Sep 22

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

TradingKey
·
Sep 22

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

TIPRANKS
·
Sep 22

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 22

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Reuters
·
Sep 22

Movement Alert|Amgen Rises 3.39% in Regular Trading, Dazodalibep Phase 3 Trial in Sjogren Disease Delivers Positive Results

Market Focus
·
Sep 22

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Sep 22

Movement Alert|Amgen Rises 4.79% in Pre-Market Trading, Dazodalibep Phase 3 Trial in Sjogren Disease Delivers Positive Results

Market Focus
·
Sep 22

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Reuters
·
Sep 22

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS
·
Sep 22

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS
·
Sep 22

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

TIPRANKS
·
Sep 22

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 22

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 21

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 19